I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

APAO 2023

-
Coming soon
05:12 PM
Duration 6mins Meeting Room 410 (Level 4)
Key Clinical Pearls for Evaluating Surgical Candidates, and Patient Preference, for the Port Delivery System With Ranibizumab
Chang A, Figueroa M, Holekamp N, Bobbala A, Menezes A, Heinrich D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:18 PM
Duration 6mins Meeting Room 410 (Level 4)
Faricimab▼ in Neovascular Age-Related Macular Degeneration: Year 1 Results With Week 12 Fluid Data From the Phase 3 TENAYA and LUCERNE Trials
Cheung G, Guymer R, Souverain A, Yang M, Kotecha A, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:24 PM
Duration 6mins Meeting Room 410 (Level 4)
VOYAGER: A Real-world Study of Faricimab▼ and the Port Delivery System With Ranibizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Chaikitmongkol V, Scheidl S, Bengus M, Guymer R, Koh A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:30 PM
Duration 6mins Meeting Room 410 (Level 4)
Key Surgical Pearls for Best Practice During the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure
Yoon YH, Wieland M, Jaycock P, Menezes A, Singh N, Malhotra V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:36 PM
Duration 6mins Meeting Room 410 (Level 4)
Port Delivery System Long-term Portal Extension Data: Three-Year Follow-up From the Phase 3 Archway Study
Hwang DK, Regillo C, Cavichini Cordeiro M, Blotner S, Jaycock P, Gune S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:30 PM
Duration 6mins Meeting Room 410 (Level 4)
Design and Rationale of the SALWEEN Trial: A Phase 3b/4 Study of Faricimab▼, a Dual Angiopoietin-2 and Vascular Endothelial Growth Factor-A Inhibitor, in Patients With Polypoidal Choroidal Vasculopathy
Lee WK, Iida T, Cheung G, Ruamviboonsuk P, Margaron P, Lai T

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:36 PM
Duration 6mins Meeting Room 410 (Level 4)
Faricimab▼ in Neovascular Age-Related Macular Degeneration (nAMD): Year 2 Patient Case Profiles From the Phase 3 TENAYA/LUCERNE Trials
Chen S, Koh A, Swaminathan B, Patel V, Margaron P, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:42 PM
Duration 6mins Meeting Room 410 (Level 4)
Durable Vision Gains and Greater Fluid Control With Extended Faricimab▼ Dosing Up to Every 16 Weeks Over 2 Years of Phase 3 YOSEMITE and RHINE Trials in DME
Lai T, Wong T, Jaffe GJ, Gerendas BS, Camino A, Tang Y, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar